Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
GMED Analyst Ratings
Moderate Buy
10 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GMED Stock 12 Month Forecast
Average Price Target
$98.08
▲(39.99% Upside)
| Highest Price Target$115.00 | Average Price Target$98.08 | Lowest Price Target$80.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
RBC Capital
Reiterated
04/15/25
Jefferies
Reiterated
04/14/25
BTIG
Reiterated
04/14/25
Truist Financial
Reiterated
04/11/25
JMP Securities
Reiterated
04/10/25
Wells Fargo
Reiterated
03/24/25
Stifel Nicolaus
Reiterated
03/18/25
Morgan Stanley
Reiterated
03/18/25
Needham
Reiterated
03/18/25
Piper Sandler
Reiterated
03/17/25
Roth MKM
$115
Buy
64.15%
Upside
Reiterated
03/13/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barclays
$100→$103
Buy
47.02%
Upside
Reiterated
02/21/25
Globus Medical price target raised to $103 from $100 at BarclaysGlobus Medical price target raised to $103 from $100 at Barclays
Bank of America Securities
$97
Hold
38.45%
Upside
Reiterated
02/21/25
Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD), Globus Medical (NYSE: GMED) and Select Medical (NYSE: SEM)We didn’t get any surprises with GMED’s full Q4 results. Q4 revenue of $657m (+5.2% day adjusted) was inline with the preannouncement and GMED had reiterated its 2025 guidance only two weeks ago when it announced the Nevro acquisition. Musculoskeletal sales grew +4.5% y/y (+3.0% day adjusted) and enabling tech grew 44% and had another record quarter of placements. $0.83 beat the on lower tax rate and better net interest. EBITDA was 4% short of the Street because of Fx. The Nevro deal was the primary focus of the call. GMED shares are down 9% since the announcement two weeks ago.
Canaccord Genuity
$101
Buy
44.16%
Upside
Reiterated
02/20/25
Globus Medical's Promising Outlook: Strong Financials, Strategic Acquisitions, and Continued Innovation Drive 'Buy' Rating
Oppenheimer
$73
Hold
4.20%
Upside
Reiterated
08/14/24
Globus Medical (GMED) Receives a Hold from Oppenheimer
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
RBC Capital
Reiterated
04/15/25
Jefferies
Reiterated
04/14/25
BTIG
Reiterated
04/14/25
Truist Financial
Reiterated
04/11/25
JMP Securities
Reiterated
04/10/25
Wells Fargo
Reiterated
03/24/25
Stifel Nicolaus
Reiterated
03/18/25
Morgan Stanley
Reiterated
03/18/25
Needham
Reiterated
03/18/25
Piper Sandler
Reiterated
03/17/25
Roth MKM
$115
Buy
64.15%
Upside
Reiterated
03/13/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barclays
$100→$103
Buy
47.02%
Upside
Reiterated
02/21/25
Globus Medical price target raised to $103 from $100 at BarclaysGlobus Medical price target raised to $103 from $100 at Barclays
Bank of America Securities
$97
Hold
38.45%
Upside
Reiterated
02/21/25
Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD), Globus Medical (NYSE: GMED) and Select Medical (NYSE: SEM)We didn’t get any surprises with GMED’s full Q4 results. Q4 revenue of $657m (+5.2% day adjusted) was inline with the preannouncement and GMED had reiterated its 2025 guidance only two weeks ago when it announced the Nevro acquisition. Musculoskeletal sales grew +4.5% y/y (+3.0% day adjusted) and enabling tech grew 44% and had another record quarter of placements. $0.83 beat the on lower tax rate and better net interest. EBITDA was 4% short of the Street because of Fx. The Nevro deal was the primary focus of the call. GMED shares are down 9% since the announcement two weeks ago.
Canaccord Genuity
$101
Buy
44.16%
Upside
Reiterated
02/20/25
Globus Medical's Promising Outlook: Strong Financials, Strategic Acquisitions, and Continued Innovation Drive 'Buy' Rating
Oppenheimer
$73
Hold
4.20%
Upside
Reiterated
08/14/24
Globus Medical (GMED) Receives a Hold from Oppenheimer
Best Analysts Covering Globus Medical
Which Analyst Should I Follow If I Want to Buy GMED and Sell After:
1 Month
xxx
Success Rate
11/20 ratings generated profit
Average Return
+1.29%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.00% of your transactions generating a profit, with an average return of +1.29% per trade.
3 Months
xxx
Success Rate
15/23 ratings generated profit
Average Return
+5.77%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +5.77% per trade.
1 Year
Success Rate
21/31 ratings generated profit
Average Return
+15.52%
reiterated a buy rating 2 months ago
Copying Matt Miksic's trades and holding each position for 1 Year would result in 67.74% of your transactions generating a profit, with an average return of +15.52% per trade.
2 Years
xxx
Success Rate
27/31 ratings generated profit
Average Return
+28.35%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 87.10% of your transactions generating a profit, with an average return of +28.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GMED Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
0
0
0
1
1
Buy
19
27
37
34
26
Hold
5
8
10
11
10
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
25
36
47
46
37
Each month's total comprises the sum of three months' worth of ratings.
GMED Financial Forecast
GMED Stock Forecast FAQ
What is GMED’s average 12-month price target, according to analysts?
Based on analyst ratings, Globus Medical’s 12-month average price target is 98.08.
What is GMED’s upside potential, based on the analysts’ average price target?
Globus Medical has 39.99% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GMED a Buy, Sell or Hold?
Globus Medical has a consensus rating of Moderate Buy which is based on 10 buy ratings, 4 hold ratings and 0 sell ratings.
What is Globus Medical’s price target?
The average price target for Globus Medical is 98.08. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $115.00 ,the lowest forecast is $80.00. The average price target represents 39.99% Increase from the current price of $70.06.
The highest analyst price target is $115.00 ,the lowest forecast is $80.00. The average price target represents 39.99% Increase from the current price of $70.06.
What do analysts say about Globus Medical?
Globus Medical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of GMED?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.